Bone Strength Reserve Screening: Current Concepts and Clinical Implications

Abstract

Bone strength reserve screening represents an evolving paradigm in musculoskeletal medicine, offering clinicians the ability to assess fracture risk beyond standard bone mineral density (BMD) measurements. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnostic modalities, and management strategies associated with bone strength reserve. Emphasis is placed on recent advances, the integration of emerging technologies, and guideline-based recommendations, aiming to inform clinical practice and optimize patient outcomes in bone health management.

Introduction

As the global burden of osteoporotic fractures rises, the limitations of relying solely on BMD for fracture risk assessment have become apparent. Bone strength reserve screening expands the clinical focus to encompass bone quality, microarchitecture, and intrinsic strength, thereby refining risk stratification and enabling earlier interventions. This review provides a comprehensive overview of the scientific basis and clinical application of bone strength reserve screening, targeting healthcare professionals involved in the management of metabolic bone diseases.

Epidemiology / Disease Burden

Osteoporotic fractures account for significant morbidity and mortality worldwide, particularly among aging populations. According to recent epidemiological data, one in three women and one in five men over the age of fifty will experience a fragility fracture during their lifetime. Despite widespread use of BMD testing, a large proportion of fractures occur in individuals with non-osteoporotic BMD values, underscoring the need for more nuanced assessment tools. The economic burden of fragility fractures is substantial, with direct healthcare costs exceeding billions annually in developed countries. These trends highlight the clinical necessity for improved screening methodologies that capture the multifactorial nature of bone strength.

Pathophysiology

Bone strength is determined by both bone quantity (BMD) and bone quality, the latter comprising parameters such as bone microarchitecture, turnover, mineralization, and the presence of microdamage. The concept of bone strength reserve refers to the intrinsic capacity of bone to withstand mechanical stress before fracturing. Deterioration in bone matrix composition, alterations in collagen cross-linking, and increased cortical porosity all contribute to reduced bone strength reserve. Mechanistically, these changes are influenced by age-related hormonal shifts, chronic inflammation, oxidative stress, and genetic factors, which collectively undermine skeletal resilience even when BMD appears preserved.

Risk Factors

Key risk factors for diminished bone strength reserve include advanced age, postmenopausal status, chronic glucocorticoid use, nutritional deficiencies (particularly calcium and vitamin D), immobility, and chronic systemic diseases such as diabetes mellitus, rheumatoid arthritis, and chronic kidney disease. Lifestyle factors such as excessive alcohol consumption, smoking, and physical inactivity further exacerbate bone fragility. Family history and genetic predisposition also play significant roles, with emerging evidence pointing to specific gene variants associated with altered bone matrix and microarchitecture.

Clinical Features

Patients with compromised bone strength reserve may remain asymptomatic until a low-trauma fracture occurs. Common clinical manifestations include vertebral compression fractures, proximal femur (hip) fractures, and distal radius fractures. Subclinical features, such as height loss, kyphosis, or chronic back pain, may suggest underlying vertebral fractures. Importantly, clinical evaluation of fracture risk should incorporate both traditional risk factors and advanced measures of bone quality to identify individuals at highest risk.

Diagnosis

While dual-energy X-ray absorptiometry (DXA) remains the gold standard for assessing BMD, it does not fully capture bone quality or predict fracture risk in all patients. Advanced diagnostic modalities, including trabecular bone score (TBS), high-resolution peripheral quantitative computed tomography (HR-pQCT), and finite element analysis (FEA), allow for detailed assessment of bone microarchitecture and mechanical competence. Biochemical markers of bone turnover (e.g., CTX, P1NP) provide adjunctive information about skeletal dynamics. Comprehensive screening protocols now advocate for an integrated approach, combining clinical risk assessment tools (e.g., FRAX), BMD, and bone strength reserve measures to optimize risk prediction and clinical decision-making.

Treatment & Management

Management strategies for individuals identified with low bone strength reserve center on fracture prevention and optimization of skeletal health. Pharmacologic therapies include bisphosphonates, denosumab, selective estrogen receptor modulators (SERMs), and anabolic agents such as teriparatide and abaloparatide. Supplementation with calcium and vitamin D, alongside lifestyle modifications (weight-bearing exercise, fall prevention), is universally recommended. Tailoring therapy based on bone strength reserve metrics may enhance individualization of treatment, especially in patients at intermediate risk or those who have failed standard therapies. Regular monitoring and re-assessment are critical to ensure sustained benefits and minimize adverse effects.

Recent Advances / Emerging Therapies

Recent technological advances have expanded the armamentarium for bone strength reserve screening. Artificial intelligence and machine learning algorithms applied to imaging and clinical datasets are enhancing risk stratification. Emerging therapies under investigation include monoclonal antibodies targeting sclerostin (romosozumab) and agents modulating Wnt signaling pathways, which show promise in improving both BMD and bone quality. Non-invasive tools such as quantitative ultrasound and magnetic resonance imaging (MRI) are also being explored for their potential in routine screening. Ongoing research aims to validate these modalities in diverse populations and integrate them into cost-effective clinical workflows.

Guideline Recommendations

International and national guidelines increasingly recognize the limitations of BMD-centric screening and endorse a multifaceted approach to fracture risk assessment. The International Osteoporosis Foundation and Endocrine Society recommend consideration of bone quality assessment, particularly in patients with a history of fractures or unexplained low-trauma injuries. Clinical risk calculators incorporating bone strength reserve parameters are advocated for use in primary and secondary prevention settings. Regular updates to guidelines reflect the rapid evolution of diagnostic and therapeutic options, emphasizing the need for ongoing clinician education and multidisciplinary collaboration.

Conclusion

Bone strength reserve screening represents a significant advance in the clinical evaluation of fracture risk, enabling healthcare professionals to move beyond traditional BMD assessment and embrace a more comprehensive understanding of skeletal health. Incorporating advanced imaging, biochemical markers, and individualized risk modeling, this approach holds the potential to improve patient outcomes through earlier detection, targeted intervention, and personalized management. Continued research and guideline refinement will further establish the clinical utility of bone strength reserve screening in diverse populations, ultimately reducing the global burden of osteoporotic fractures.